# UmbREALung - A Retrospective and Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance

> **NCT06726720** · — · RECRUITING · sponsor: **AstraZeneca** · enrollment: 300 (estimated)

## Conditions studied

- Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06726720
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-16
- **Primary completion:** 2032-06-30
- **Final completion:** 2032-06-30
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06726720

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06726720, "UmbREALung - A Retrospective and Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06726720. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*